These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1472830)

  • 1. Microalbuminuria is no risk factor for restenosis following percutaneous transluminal coronary angioplasty.
    Toplak H; Schumacher M; Eber B; Luha O; Klein W; Krejs GJ
    Clin Investig; 1992 Nov; 70(11):1010-2. PubMed ID: 1472830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restenosis after delayed coronary angioplasty of the culprit vessel in patients with a recent myocardial infarction treated by thrombolysis.
    Bauters C; Khanoyan P; McFadden EP; Quandalle P; Lablanche JM; Bertrand ME
    Circulation; 1995 Mar; 91(5):1410-8. PubMed ID: 7867181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary stenting or balloon angioplasty for chronic total coronary occlusions: the Taiwan experience (a single-center report).
    Fang CC; Jao YT; Chen Y; Wang SP
    Angiology; 2005; 56(5):525-37. PubMed ID: 16193191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of restenosis 10 years after coronary angioplasty.
    Espinola-Klein C; Rupprecht HJ; Erbel R; Nafe B; Brennecke R; Meyer J
    Eur Heart J; 1998 Jul; 19(7):1047-53. PubMed ID: 9717040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
    Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
    J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prediction of restenosis after percutaneous transluminal coronary angioplasty using coronary flow reserve. Kansai Doppler Guide Wire Study Group].
    Toda I; Teragaki M; Nishida Y; Kobayashi Y; Shimada K; Yoshiyama M; Akioka K; Takeuchi K; Yoshikawa J
    J Cardiol; 2000 Mar; 35(3):165-73. PubMed ID: 10808423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty.
    Eber B; Schumacher M; Auer-Grumbach P; Toplak H; Klein W
    Am J Cardiol; 1992 May; 69(16):1255-8. PubMed ID: 1585855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease.
    Miyata M; Biro S; Arima S; Hamasaki S; Kaieda H; Nakao S; Kawataki M; Nomoto K; Tanaka H
    Am Heart J; 1996 Aug; 132(2 Pt 1):269-73. PubMed ID: 8701886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty.
    Alaigh P; Hoffman CJ; Korlipara G; Neuroth A; Dervan JP; Lawson WE; Hultin MB
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1281-6. PubMed ID: 9714135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angiography.
    Schumacher M; Eber B; Tiran A; Toplak H; Luha O; Gasser R; Klein W
    Cardiology; 1992; 80(5-6):345-8. PubMed ID: 1451121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of restenosis after successful primary coronary angioplasty for acute myocardial infarction: the importance of age and procedural result.
    van 't Hof AW; de Boer MJ; Suryapranata H; Hoorntje JC; Zijlstra F
    Am Heart J; 1998 Sep; 136(3):518-27. PubMed ID: 9736147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.